knowledge -WSS

knowledge

author：explore 2025-09-29 10:13:57 Page View：4

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Chicago flooding is stark reminder of vulnerability of major cities during extreme weather
Next article： How to save PrEP access — and even expand it

Wikipedia

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Many breast cancer patients receive more radiation than needed

KathiKolb,aRhodeIslandphysicaltherapist,saysshe’sfrustratedthatfewerthanhalfofeligiblebreastcancerpa

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

With heat waves through August, officials warn of health risks

Analreadyrecord-settingsummerheatwavewillcontinuethroughAugustandwillputmorethan51millionAmericansat